Location History:
- Patrica Fr, IT (2008)
- Rome, IT (2010)
- Patricia, IT (2015)
- Patrica, IT (2011 - 2016)
Company Filing History:
Years Active: 2008-2016
Title: The Innovative Contributions of Umberto Ciambecchini
Introduction
Umberto Ciambecchini is a notable inventor based in Patrica, Italy. He has made significant contributions to the field of pharmaceuticals, holding a total of nine patents. His work focuses on the development of innovative methods and formulations that enhance the efficacy and purity of various compounds.
Latest Patents
One of Ciambecchini's latest patents is a method for preparing high-purity fesoterodine fumarate. This process involves the salification reaction of fesoterodine with fumaric acid in an organic solvent, preferably a ketone, at a temperature not exceeding 45°C. This method allows for the production of high-yield and high-purity products, specifically achieving a content of (2E)-4-[(3-(3-diisopropylamino-1-phenylpropyl)-4-(2-isobutyroyloxyphenyl)methoxy]-4-oxobut-2-enoic acid of less than or equal to 0.15% by mole. Another significant patent involves bortezomib esters and formulations thereof, which describe bortezomib esters with tartaric acid in a molar ratio of 2:1, along with formulations containing these esters.
Career Highlights
Ciambecchini is currently associated with Chemi S.p.a., where he continues to innovate in the pharmaceutical sector. His work has been instrumental in advancing drug formulations that are both effective and safe for consumer use.
Collaborations
Throughout his career, Ciambecchini has collaborated with esteemed colleagues such as Stefano Turchetta and Maurizio Zenoni. These partnerships have fostered a collaborative environment that encourages the exchange of ideas and expertise.
Conclusion
Umberto Ciambecchini's contributions to the field of pharmaceuticals through his innovative patents highlight his role as a leading inventor. His work not only advances scientific knowledge but also enhances the quality of healthcare products available to the public.